Compare · EVMN vs LLY
EVMN vs LLY
Side-by-side comparison of Evommune Inc. (EVMN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 1488.2x EVMN ($727.2M).
- Over the past year, EVMN is up 3.9% and LLY is up 48.0% - LLY leads by 44.1 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 13 for EVMN).
- LLY has more recent analyst coverage (25 ratings vs 10 for EVMN).
- Company
- Evommune Inc.
- Eli Lilly and Company
- Price
- $20.60+2.23%
- $1145.13-0.41%
- Market cap
- $727.2M
- $1.08T
- 1M return
- -9.91%
- +20.69%
- 1Y return
- +3.89%
- +47.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 13
- 17
- Recent ratings
- 10
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest EVMN
- SEC Form 4 filed by Director Mcgraw Benjamin F Iii
- SEC Form 4 filed by Director Kirsch Arthur S
- Director Cohen David E sold $123,094 worth of shares (6,056 units at $20.33) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 17,609 units (SEC Form 4)
- Chief Scientific Officer Patel Jeegar Pravinkumar sold $379,462 worth of shares (16,687 units at $22.74) as part of a pre-agreed trading plan and exercised 13,512 shares at a strike of $3.84, decreasing direct ownership by 6% to 46,403 units (SEC Form 4)
- President & CEO Pena Luis C. sold $381,736 worth of shares (16,787 units at $22.74) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 637,896 units (SEC Form 4)
- SEC Form 144 filed by Evommune Inc.
- SEC Form 424B3 filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Business & Legal Officer Moss Gregory S. exercised 14,223 shares at a strike of $1.71 and sold $324,711 worth of shares (14,223 units at $22.83) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Carver Kyle exercised 15,000 shares at a strike of $2.99 and sold $415,117 worth of shares (18,175 units at $22.84) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 59,335 units (SEC Form 4)
Latest LLY
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets